BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Convention Name August 4, 2025 4:30 PM ET
Firm Individuals
Alexander Hardy – President, CEO & Director
Brian R. Mueller – Government VP of Finance & CFO
Cristin Hubbard – Government VP & Chief Industrial Officer
Gregory Friberg – Government VP and Chief Analysis & Improvement Officer
Traci McCarty – Group Vice President
Convention Name Individuals
Akash Tewari – Jefferies LLC, Analysis Division
Alexandria Janet Hammond – Wolfe Analysis, LLC
Allison Marie Bratzel – Piper Sandler & Co., Analysis Division
Cory William Kasimov – Evercore ISI Institutional Equities, Analysis Division
Ellen Horste – TD Cowen, Analysis Division
Huidong Wang – Barclays Financial institution PLC, Analysis Division
Jasmine Alexandra Fels – UBS Funding Financial institution, Analysis Division
Jason Matthew Gerberry – BofA Securities, Analysis Division
Konstantinos Biliouris – BMO Capital Markets Fairness Analysis
Olivia Simone Brayer – Cantor Fitzgerald & Co., Analysis Division
Paul Andrew Matteis – Stifel, Nicolaus & Firm, Integrated, Analysis Division
Sean M. Laaman – Morgan Stanley, Analysis Division
Tommie M. Reerink – Goldman Sachs Group, Inc., Analysis Division
Operator
Good afternoon. My title is Audra, and I shall be your convention operator at this time. Presently, I want to welcome everybody to the BioMarin Prescription drugs Second Quarter 2025 Convention Name. Right this moment’s convention is being recorded. [Operator Instructions]
Presently, I want to flip the convention over to Traci McCarty, Investor Relations at BioMarin. Please go forward.
Traci McCarty
Thanks, operator. To remind you, this nonconfidential presentation incorporates forward-looking statements in regards to the enterprise prospects of BioMarin Pharmaceutical Inc., together with expectations relating to BioMarin’s monetary efficiency, business merchandise and potential future merchandise in numerous areas of therapeutic analysis and improvement. Outcomes might differ materially relying on the progress of BioMarin’s product packages, actions of regulatory authorities, availability of capital, future actions within the pharmaceutical market and developments by opponents and
